Company Profile
CSPC Pharmaceutical Group Limited, an investment holding company provides the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and globally.
Its business is organized into Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke.
Its portfolio also includes Oulaining capsules and injections to treat mild to moderate memory and mental impairment, Enxi to treat adult idiopathic Parkinson's disease, Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and malignant tumors, Jinyouli to prevent infection induced by chemotherapy, and Keaili for breast cancer Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections.
Its portfolio also includes Xuanning for hypertension, Encun to prevent atherosclerotic thrombosis events, Qixiao to treat upper respiratory tract infection, Linmeixin and Shuanglexin for diabetes, Gubang and Gubangjia to treat osteoporosis in postmenopausal women, and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and soft tissue injuries.
Additionally, it provides Debixin for various ulcer. Its portfolio also includes Qimaite for acute and chronic pains, antibiotics, vitamin C, and caffeine APIs, functional food products, and healthcare services.
It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes.
Incorporated in 1992 and headquartered in Shijiazhuang, the People's Republic of China, CSPC Pharmaceutical was formerly known as China Pharmaceutical Group Limited before rebranding in March 2013.